Interventions for healthcare and country-wide settings

• Professor Charlotte Bevan: Convergence science approaches to drug delivery and biomarker detection. Example (in Covid): Repurposing of drugs for COVID-19.
• Professor Joseph Boyle: Drug repurposing and interventions with TRV027 an antagonist of Angiotensin-II.
• Professor Rongjun Chen: Polymer- and lipid-based nanoparticles for targeted delivery of active pharmaceutical agents including nucleic acids and proteins. In Covid (example): Thermostable RNA formulations for vaccines and therapeutics.
• Dr Jun Ishihara: Drug design and translational immunology. Example (in Covid): Engineering of protein-based drugs that deal with cytokine storm inflammation after SARS-CoV-2 infection. 
• Professor David Mann: Inhibitor drug discovery. Example (in Covid): Acrylamide inhibitors for the treatment of Covid-19.
• Dr Laura Martin Sancho: Identification of targets for host-directed antiviral therapies and antiviral testing through large scale screening.
• Dr Michela Noseda: Using computational pipelines for in silico drug screening leveraging single-cell and spatial transcriptomics datasets.
• Dr Brijesh Patel: Repurposing of biologics that target fibroproliferation, with the aim of preventing fibrosis in at-risk patients. Example (in Covid): New therapies and repurposed therapies for severe COVID-19 by investigating key driving signatures of fibrosis and necrosis in the lungs.
• Professor Anna Randi: Vascular biology and vascular haemostasis. Example (in Covid): Anti-thrombotic drugs for severe COVID-19 infection.
• Dr Anna Reed: Respiratory and transplant medicine, e.g., immunomodulatory therapy.

• Professor Graham Cooke: Clinical translation, treatment decision-making, access to medicine, patient safety. Example (in Covid): COVID-19 treatment guidelines group.
• Professor Aldo Faisal: Artificial intelligence for clinical decision-making. Example (in Covid): AI prediction of best treatment for Covid-19 patients.
• Professor Anthony Gordon: Clinical and translational research. Example: Assessing treatments for critically ill COVID-19 patients in an adaptive platform trial – REMAP-CAP.
• Professor Alison Holmes: Antimicrobial resistance. Example (in Covid): AI for clinical decision-making around antibiotic prescriptions for COVID-19 patients.
• Professor Peter Openshaw: Scientific advice on the use of antivirals in respiratory infections and pandemic preparedness.
• Dr Elizabeth Whittaker: Treatment of influenza (anti-virals, immune modulation) and exploring their impact on viral resistance (via REMAP CAP platform trial). 

• Dr Marc Masen:  Interaction of the human body with (medical) devices; Friction science for clinical applications, including PPE for healthcare workers. Example (in Covid): Lubricant performance to reduce COVID-19 PPE-related skin injury.
• Dr Jakob Mathiszig-Lee: Low-cost ventilators for use in LMICs.
• Professor Cecilia Mattevi: Nanotechnology solutions for infection, including self-disinfecting surfaces (e.g. for masks/air-filter devices), drug delivery, and diagnostics. Example (in Covid): Toward nanotechnology-enabled approaches against the COVID-19 pandemic.
• Dr Connor Myant: Advanced manufacturing and design engineering. Example (in Covid): Custom-made PPE for frontline healthcare workers.
• Dr Jonathan Otter: Healthcare epidemiology and infection prevention and control. Example (in Covid): Healthcare SARS-CoV-2 transmission and interventions (e.g., precision prescribing, HEPA-based air decontamination systems, single patient rooms).
• Miss Catherine Rennie: Engineering solutions to reducing the spread of aerosols in hospital wards. Example (in Covid): Development of Zephyr hood – an aerosol contaminant device.
• Professor Elio Riboli: Cancer epidemiology and prevention. Example (in Covid): Understanding and interventions for the accumulating number of undiagnosed cases of cancer and cardiovascular disease due to the COVID-19 pandemic.
• Dr Antonis Sergis: Laser optics and software to study aerosol generation. Example (in Covid): New protocols for safe delivery of dental care during Covid-19.
• Dr Joseph van Batenburg-Sherwood: Low-cost ventilators for use in LMICs.

• Professor Marisa Miraldo: Incentives for innovation and access to innovation. Example: Hi-Prix project: Balancing sustainability of innovation with sustainability of healthcare. 
• Professor Esther Rodriguez-Villegas: Low-power electronics and app design. Example (in Covid): Contact tracing app for Covid-19 built on privacy design principles.  
• Dr Kirill Veselkov: Computation and AI for health and disease; AI to identify bioactive compounds in foods with antiviral properties; precision nutrition strategies to support future pandemic preparedness. Example (in Covid): An AI-powered patient triage platform for future viral outbreaks; 'hyperfoods' to target SARS-CoV-2 host-pathogen interactions. 

Explore Imperial's vaccine expertise for pandemic preparedness.